3 completed, 1 recruiting, 1 terminated, 1 unknown. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Limb-girdle muscular dystrophy, type 2E: new trials by email Literature Review of Limb-girdle muscular dystrophy, type 2E trials Research Report on Limb-girdle muscular dystrophy, type 2E
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-Term Development of Muscular Dystrophy Outcome Assessments LGMD1B, LGMD1C | Recruiting | Virginia Commonwealth University | 1000 | 2023-10-18 | 2025-11-18 | |
| Clinical Determinants of Disease Progression in Patients With Limb Girdle Muscular Distrophy Type 2E Exon 3 truncating mutation, Any other mutation in SGBC gene - LGMD2E | Completed | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 33 | 2020-06-01 | 2022-03-31 | |
| Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency) SRP-9003 - Limb-Girdle Muscular Dystrophy, Type 2E | Phase 1 / Phase 2 | Terminated | Sarepta Therapeutics, Inc. | 6 | 2018-10-27 | 2026-01-20 |
| Limb Girdle Muscular Dystrophy Type 2E Recruitment Study Limb-Girdle Muscular Dystrophy, Type 2E | Unknown | Nationwide Children's Hospital | 25 | 2018-03-28 | 2023-03-06 | |
| Natural History of Limb Girdle Muscular Dystrophy Type 2A and Type 2E Limb-Girdle Muscular Dystrophy Type 2A, Limb-Girdle Muscular Dystrophy, Type 2E | Completed | Lindsay Alfano | 100 | 2016-11-29 | 2025-08-14 | |
| Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH) Riociguat (ADEMPAS, BAY63-2521) - Hypertension, Pulmonary | Completed | Bayer | 882 | 2015-06-29 | 2024-01-29 |
Muscular Dystrophies, Limb-Girdle (3) · Limb-girdle muscular dystrophy type 2A (2) · Sarcoglycanopathies (2) · Hypertension, Pulmonary (1) · Limb-Girdle Muscular Dystrophy, Type 1G (1) · Limb-girdle muscular dystrophy type 2F (1) · Limb-girdle muscular dystrophy, type 1B (1) · Limb-girdle muscular dystrophy, type 2B (1) · Limb-girdle muscular dystrophy, type 2C (1) · Muscular Dystrophies (1) · Muscular Dystrophy, Limb-Girdle, Type 1C (1) · Muscular Dystrophy, Limb-Girdle, Type 1D (1) · Muscular Dystrophy, Limb-Girdle, Type 1E (1) · Muscular Dystrophy, Limb-Girdle, Type 1F (1)
Cardiovascular Diseases (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Muscular Diseases (3) · Muscular Disorders, Atrophic (3) · Musculoskeletal Diseases (3) · Nervous System Diseases (3) · Neuromuscular Diseases (3) · Respiratory Tract Diseases (3) · Cardiomyopathies (2) · Heart Diseases (2) · Muscular Dystrophies (2) · Respiration Disorders (2) · Cobblestone Lissencephaly (1) · Congenital Abnormalities (1)
riociguat (1)
Bayer (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · Lindsay Alfano (1) · Nationwide Children's Hospital (1) · Sarepta Therapeutics, Inc. (1) · Virginia Commonwealth University (1)
United States (4) · Italy (1) · Japan (1)
Jerry R Mendell, M.D. (1) · Linda Lowes, PT PhD (1) · Nicholas Johnson, MD (1)